Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$11.47
$2.66
$32.75
$48.64M2.5795,409 shs43,300 shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.02
$9K0.7913,056 shs1 shs
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
$0.38
$0.38
$0.36
$4.80
$1.43MN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
$0.02
$1.46
$0.94
$5.70
$1.50M0.9698,414 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00%0.00%0.00%0.00%0.00%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%+150.00%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00%0.00%0.00%0.00%0.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-59.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00
N/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00
N/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$2.33M0.00N/AN/A($60.61) per share0.00
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
$220K6.82N/AN/A$0.63 per share0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/A7/7/2025 (Estimated)
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
-$4.37MN/A0.00N/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
-$18.95MN/A0.00N/A-8,633.64%-43.94%-28.92%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
4.59
4.59
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/A
0.80
0.73
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
694.05 million3.78 millionOptionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
403.75 million3.46 millionNot Optionable
OASM
Oasmia Pharmaceutical AB (publ)
5774.97 millionN/ANot Optionable

Recent News About These Companies

Double Bond Pharmaceutical International AB (DBPHAb)
Sector-Health Care & Pharmaceuticals
BOEUF Bonesupport Holding AB (publ)
Lipigon Pharmaceuticals AB LPGO
Resurs Holding AB (publ) (RESURS.ST)
QuiaPEG Pharmaceuticals Holding AB QUIA
Newbury Pharmaceuticals AB (NEWBRY)
Lipigon Pharmaceuticals AB (LPGO)
Speqta publ AB (SPEQT)
PRXXF Paradox Interactive AB (publ)
Notice of annual general meeting in Alzinova AB (publ)
Oasmia expands R&D ability with planned laboratory upgrade

Media Sentiment Over Time

Aeglea BioTherapeutics stock logo

Aeglea BioTherapeutics NASDAQ:AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)
As of 07/3/2025

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NeuBase Therapeutics stock logo

NeuBase Therapeutics NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Oasmia Pharmaceutical AB (publ) NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.